CN103732062A - 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法 - Google Patents

治疗多发性硬化以及保持和/或增加髓磷脂含量的方法 Download PDF

Info

Publication number
CN103732062A
CN103732062A CN201280036988.6A CN201280036988A CN103732062A CN 103732062 A CN103732062 A CN 103732062A CN 201280036988 A CN201280036988 A CN 201280036988A CN 103732062 A CN103732062 A CN 103732062A
Authority
CN
China
Prior art keywords
subject
fumarate
treatment
years
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280036988.6A
Other languages
English (en)
Chinese (zh)
Inventor
凯瑟琳·达森
吉尔摩·奥尼尔
阿尔佛雷德·桑德洛克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103732062(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN103732062A publication Critical patent/CN103732062A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280036988.6A 2011-05-26 2012-05-25 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法 Pending CN103732062A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161490572P 2011-05-26 2011-05-26
US61/490,572 2011-05-26
US201261625624P 2012-04-17 2012-04-17
US61/625,624 2012-04-17
PCT/US2012/039721 WO2012162669A1 (en) 2011-05-26 2012-05-25 Methods of treating multiple sclerosis and preserving and/or increasing myelin content

Publications (1)

Publication Number Publication Date
CN103732062A true CN103732062A (zh) 2014-04-16

Family

ID=47217796

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280036988.6A Pending CN103732062A (zh) 2011-05-26 2012-05-25 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法

Country Status (19)

Country Link
US (1) US20140163100A1 (https=)
EP (1) EP2713724A4 (https=)
JP (1) JP2014515373A (https=)
KR (1) KR20140036257A (https=)
CN (1) CN103732062A (https=)
AU (1) AU2012258558A1 (https=)
BR (1) BR112013030169A2 (https=)
CA (1) CA2836480A1 (https=)
CL (1) CL2013003358A1 (https=)
CO (1) CO6811862A2 (https=)
EA (1) EA201391578A1 (https=)
EC (1) ECSP13013117A (https=)
IL (1) IL229448A0 (https=)
MX (1) MX2013013781A (https=)
PE (1) PE20141316A1 (https=)
PH (1) PH12013502443A1 (https=)
SG (1) SG195049A1 (https=)
WO (1) WO2012162669A1 (https=)
ZA (1) ZA201308681B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106530A (zh) * 2014-11-17 2017-08-29 比奥根玛公司 治疗多发性硬化的方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526586C (en) 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
KR20150080037A (ko) 2011-06-08 2015-07-08 바이오젠 엠에이 인코포레이티드 고순도 및 결정질 다이메틸 푸마레이트의 제조 방법
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CA2882730C (en) 2012-08-22 2019-12-31 Arbor Pharmaceuticals, Llc Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
WO2014031901A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of use for monomethyl fumarate and prodrugs thereof
EP2934503B1 (en) 2012-12-21 2019-04-10 Biogen MA Inc. Deuterium substituted fumarate derivatives
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
CN103724198A (zh) * 2013-11-28 2014-04-16 镇江圣安医药有限公司 富马酸二甲酯的新型衍生物及其应用
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
JP6564868B2 (ja) * 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
KR20200013086A (ko) 2014-12-11 2020-02-05 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1257426A (zh) * 1997-05-20 2000-06-21 富玛法姆股份公司 富马酸衍生物的应用
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
US20100048651A1 (en) * 2008-08-19 2010-02-25 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
EP2680010A1 (en) * 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
JP2012525385A (ja) * 2009-04-29 2012-10-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経変性および神経炎症の治療

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1257426A (zh) * 1997-05-20 2000-06-21 富玛法姆股份公司 富马酸衍生物的应用
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
US20100048651A1 (en) * 2008-08-19 2010-02-25 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUDWIG KAPPOS 等: ""Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study"", 《THE LANCET》, vol. 372, no. 9648, 25 October 2008 (2008-10-25), pages 1463 - 1, XP025584415, DOI: doi:10.1016/S0140-6736(08)61619-0 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106530A (zh) * 2014-11-17 2017-08-29 比奥根玛公司 治疗多发性硬化的方法
US10959972B2 (en) 2014-11-17 2021-03-30 Biogen Ma Inc. Methods of treating multiple sclerosis
US11007166B2 (en) 2014-11-17 2021-05-18 Biogen Ma Inc. Methods of treating multiple sclerosis
US11007167B2 (en) 2014-11-17 2021-05-18 Biogen Ma Inc. Methods of treating multiple sclerosis
US11129806B2 (en) 2014-11-17 2021-09-28 Biogen Ma Inc. Methods of treating multiple sclerosis
US11246850B2 (en) 2014-11-17 2022-02-15 Biogen Ma Inc. Methods of treating multiple sclerosis
CN115531366A (zh) * 2014-11-17 2022-12-30 渤健马萨诸塞州股份有限公司 治疗多发性硬化的方法

Also Published As

Publication number Publication date
ZA201308681B (en) 2017-11-29
BR112013030169A2 (pt) 2016-08-09
MX2013013781A (es) 2014-01-08
SG195049A1 (en) 2013-12-30
EA201391578A1 (ru) 2014-05-30
IL229448A0 (en) 2014-01-30
CA2836480A1 (en) 2012-11-29
US20140163100A1 (en) 2014-06-12
EP2713724A4 (en) 2015-03-11
ECSP13013117A (es) 2014-06-30
PE20141316A1 (es) 2014-10-01
PH12013502443A1 (en) 2019-03-22
CL2013003358A1 (es) 2014-08-01
CO6811862A2 (es) 2013-12-16
WO2012162669A1 (en) 2012-11-29
EP2713724A1 (en) 2014-04-09
JP2014515373A (ja) 2014-06-30
KR20140036257A (ko) 2014-03-25
AU2012258558A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
CN103732062A (zh) 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法
JP5474276B2 (ja) 高脂血症治療剤
EP2139467B1 (en) Neuroprotection in demyelinating diseases
US20140329786A1 (en) Combination treatment of cancer
JP2015512406A5 (https=)
JP2004518653A (ja) 不安障害を治療する方法
KR102902972B1 (ko) Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물
AU2008259864C1 (en) Methods and compositions for administration of Oxybutynin
MX2009002311A (es) Composiciones farmaceuticas para tratamiento de infecciones fungales.
JP2004525940A (ja) 火照りの処置のためのデュロキセチン
JP2022504184A (ja) ブドウ膜黒色腫の治療のための併用療法
JP4972156B2 (ja) ＶＩ型コラーゲン欠損に起因する先天性筋ジストロフィーまたはミオパシーの予防および／または処置のためのＮ−（ジベンゾ（ｂ，ｆ）オキセピン−１０−イルメチル）Ｎ−メチル−Ｎ−プロプ−２−イニルアミン（オミガピル）の使用法
JP2025504447A (ja) アスピリン及びその他のｎｓａｉｄの高透過プロドラッグによる心血管疾患の予防又は治療
WO2023066330A1 (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
EA010868B1 (ru) Применение производных бицикло[2.2.1]гептана для приготовления нейропротекторных фармацевтических композиций
JP2019534336A (ja) 多発性骨軟骨腫（ｍｏ）を処置するための方法
JP2004002362A (ja) くしゃみ抑制組成物
US20140186271A1 (en) Reducing dental caries
CN115364102B (zh) 一种吡咯并嘧啶类化合物的应用
US20060281817A1 (en) Treatment for neurodegenerative diseases
WO2004096276A9 (ja) 糖取り込み能増強剤
WO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤
JPS6011422A (ja) 抗筋ジストロフイ−症剤
CN1084622C (zh) 药物
JP5707137B2 (ja) レバミピドの骨粗鬆症治療用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140416